AU2010217160C1 - Method for detecting metastasis of GI cancer - Google Patents

Method for detecting metastasis of GI cancer Download PDF

Info

Publication number
AU2010217160C1
AU2010217160C1 AU2010217160A AU2010217160A AU2010217160C1 AU 2010217160 C1 AU2010217160 C1 AU 2010217160C1 AU 2010217160 A AU2010217160 A AU 2010217160A AU 2010217160 A AU2010217160 A AU 2010217160A AU 2010217160 C1 AU2010217160 C1 AU 2010217160C1
Authority
AU
Australia
Prior art keywords
gcc
cancer
gusb
sample
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010217160A
Other languages
English (en)
Other versions
AU2010217160B2 (en
AU2010217160A1 (en
Inventor
Guillaume Beaudry
Martin Beaulieu
Nicolas Bertrand
Genevieve Garon
Jean-Francois Haince
Timothy J. Holzer
Michel Houde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnocure Inc
Original Assignee
Diagnocure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnocure Inc filed Critical Diagnocure Inc
Publication of AU2010217160A1 publication Critical patent/AU2010217160A1/en
Application granted granted Critical
Publication of AU2010217160B2 publication Critical patent/AU2010217160B2/en
Publication of AU2010217160C1 publication Critical patent/AU2010217160C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2010217160A 2009-02-25 2010-02-24 Method for detecting metastasis of GI cancer Ceased AU2010217160C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15517209P 2009-02-25 2009-02-25
US61/155,172 2009-02-25
US24619709P 2009-09-28 2009-09-28
US61/246,197 2009-09-28
PCT/CA2010/000277 WO2010096929A1 (en) 2009-02-25 2010-02-24 Method for detecting metastasis of gi cancer

Publications (3)

Publication Number Publication Date
AU2010217160A1 AU2010217160A1 (en) 2011-09-22
AU2010217160B2 AU2010217160B2 (en) 2014-11-20
AU2010217160C1 true AU2010217160C1 (en) 2015-07-02

Family

ID=42664977

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010217160A Ceased AU2010217160C1 (en) 2009-02-25 2010-02-24 Method for detecting metastasis of GI cancer

Country Status (7)

Country Link
US (1) US20110306055A1 (https=)
EP (2) EP2677036A3 (https=)
JP (1) JP2012518389A (https=)
CN (1) CN102333887B (https=)
AU (1) AU2010217160C1 (https=)
CA (1) CA2752668A1 (https=)
WO (1) WO2010096929A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
US9416410B2 (en) * 2012-02-14 2016-08-16 Genetics Development Corporation Cutoff point delta Ct. method for HER2 PCR testing in breast cancer
ME03560B (me) 2012-04-27 2020-07-20 Millennium Pharm Inc MOLEKULI ANTI-GCC ANTITELA l NJIHOVA UPOTREBA U ISPITIVANJU OSETLJIVOSTI NA GCC-CILJANU TERAPIJU
WO2016028141A1 (en) * 2014-08-18 2016-02-25 Universiti Kebangsaan Malaysia Method for determining prognosis of colorectal cancer
EP4706525A3 (en) 2014-09-25 2026-04-22 BT Bidco, Inc. Electromechanical pill device with localization capabilities
EP3500177A1 (en) * 2016-08-18 2019-06-26 Mitchell Lawrence Jones Systems for obtaining samples using ingestible devices
KR20230042759A (ko) 2016-09-09 2023-03-29 비오라 쎄라퓨틱스, 인크. 분배가능한 물질의 전달을 위한 전자기계식 섭취가능한 디바이스
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US11761032B2 (en) * 2017-03-11 2023-09-19 Yan Wang Methods and devices for performing real time digital PCR
EP3900613B1 (en) 2017-03-31 2023-12-27 Biora Therapeutics, Inc. Localization methods for an ingestible device
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN110819715A (zh) * 2019-11-26 2020-02-21 华夏帮服科技有限公司 用于结直肠癌检测的免疫基因标志物及试剂盒
CN118460719A (zh) * 2020-03-02 2024-08-09 腾辰生物科技(上海)有限公司 一种分子标志物及试剂盒在辅助诊断食管癌中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
EP0734264B1 (en) 1993-10-26 2004-02-18 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
WO1997042506A1 (en) 1996-05-03 1997-11-13 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
AU2001249548A1 (en) 2000-03-27 2001-10-08 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
US7138226B2 (en) 2002-05-10 2006-11-21 The University Of Miami Preservation of RNA and morphology in cells and tissues
US20040018494A1 (en) * 2002-07-25 2004-01-29 Shurtliff Roxanne N Isothermal transcription based amplification assay for detection and quantification of guanylyl cyclase C
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer

Also Published As

Publication number Publication date
EP2401394B1 (en) 2013-11-27
JP2012518389A (ja) 2012-08-16
CN102333887A (zh) 2012-01-25
EP2677036A2 (en) 2013-12-25
EP2677036A3 (en) 2014-01-22
CA2752668A1 (en) 2010-09-02
HK1165836A1 (en) 2012-10-12
WO2010096929A1 (en) 2010-09-02
EP2401394A1 (en) 2012-01-04
US20110306055A1 (en) 2011-12-15
AU2010217160B2 (en) 2014-11-20
EP2401394A4 (en) 2012-07-11
CN102333887B (zh) 2014-04-02
AU2010217160A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
AU2010217160C1 (en) Method for detecting metastasis of GI cancer
US10494677B2 (en) Predicting cancer outcome
ES2925983T3 (es) Método para usar la expresión génica para determinar el pronóstico del cáncer de próstata
Kanda et al. The expression of melanoma-associated antigen D2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression
WO2009036427A2 (en) Prostate cancer biomarkers
Bournet et al. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples
ES2914727T3 (es) Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata
US20130303400A1 (en) Multimarker panel
US9606122B2 (en) Prognosis of oesophageal and gastro-oesophageal junctional cancer
KR102036222B1 (ko) 당뇨병성 신증에 의한 만성신장질환 환자의 예후 예측용 마커
Labuhn et al. Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR
CA2760050A1 (en) Guanylyl cyclase c qrt-pcr
AU2009216723B2 (en) BRCA1 mRNA expression predicts survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy
HK1165836B (en) Method for detecting metastasis of gi cancer
US7358060B2 (en) Method for monitoring and prognosis of disease course of gastrointestinal tumors
EP4317458A1 (en) Follicular thyroid cancer-specific marker
KR102036219B1 (ko) 유전자 프로모터의 CpG 메틸화 변화를 이용한 만성신장질환의 악화 예측용 조성물 및 이의 이용
KR102036220B1 (ko) 만성신장질환 특이적 후성학적 메틸화 마커 검출용 조성물 및 검출방법
KR102036221B1 (ko) 만성신장질환의 예후 예측을 위한 후성 유전학적 진단 키트 개발
Troyer et al. Quantitation of TMPRSS2: ERG fusion transcripts in frozen and paraffin embedded prostate cancers (PC)
KR20170012816A (ko) Cirp 유전자의 발현 수준을 측정하는 제제를 포함하는 대장암 예후 예측용 조성물

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 FEB 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 FEB 2015

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired